Morrisville / North Carolina / United States
About Oxygen Biotherapeutics Oxygen Biotherapeutics, Inc, is dedicated to commercializing innovative pharmaceuticals and medical devices in the field of oxygen therapeutics and Defense Medicine. The company has under development a perfluorocarbon ( PFC ) therapeutic oxygen carrier and liquid ventilation product ( OXYCYTE ) and has out-licensed an implantable glucose sensor. These products are based upon core technologies that include biomedical applications for PFCs as well as medical and industrial applications for biosensors. The company believes OXYCYTE has the potential for use in multiple indications, including traumatic brain injury, sickle cell crisis pain, trauma, wound care, decompression sickness, acute respiratory distress syndrome, stroke, myocardial infarction, surgery, diabetes and cosmetic applications. April 7, 2010 Oxygen Biotherapeutics, Inc ( NASDAQ: OXBT ) today announced that its Chairman and CEO Chris Stern will present at the Swiss Equity Biotech Conference at the SIX Swiss Exchange Convention Point in Zurich, Switzerland on Tuesday, April 13 at 8 AM ( EDT ). This conference is presented by Swiss Equity magazine in conjunction with the Swiss Biotech Association and SIX Swiss Exchange. Stern will provide an overview of the companys programs and products. The conference includes presentations by public and privately held companies as well as expert views on current business and science trends. For more information on the conference, visit www.biotechday.ch.
